•Interventional Cardiologist • Clinical Professor of Medicine: #Aging •Dean’s Scholar: #Finance #Biotech @NYUStern •Mesopotamian
🥸 1️⃣ CLOSURE-AF: Among patients with atrial fibrillation at high risk for both stroke and bleeding, catheter-based left atrial appendage closure was NOT noninferior to physician-directed best medical care. This is a major finding with direct clinical implications to practice.
🥸1️⃣ Lipid-lowering therapy is a cornerstone of cardiovascular risk reduction in older adults. However, concerns about possible cognitive side effects, especially in the setting of aggressive low-density lipoprotein cholesterol reduction, persist among patients and clinicians.
🥸1️⃣Social and economic conditions shape cardiovascular aging as strongly as traditional risk factors. These exposures begin early, accumulate over decades, and alter vascular, myocardial, valvular, and electrophysiologic aging trajectories.
🥸 1️⃣ Inflammation and cardiovascular disease frames risk beyond cholesterol; residual inflammatory risk by hsCRP often persists despite statins, so a patient with LDL at goal but hsCRP 3–5 mg/L still faces higher event rates and needs a plan that targets inflammation directly.
🥸1️⃣ For decades, aspirin has been the default long-term therapy for preventing recurrent cardiovascular events in patients with established coronary artery disease. It has been embedded in clinical guidelines based largely on historical data.
🥸1️⃣ GLP-1 receptor agonists (GLP-1RAs) were originally developed for diabetes and weight loss. SELECT expanded their role, showing semaglutide reduces cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease.
🥸1️⃣ The POTCAST trial tested if raising potassium to the high-normal range (4.5–5.0 mmol/L) reduces malignant arrhythmias, hospitalizations, or death in patients with cardiovascular disease and an implanted defibrillator.
🥸1️⃣ The REBOOT trial evaluated beta-blockers after MI in patients with LVEF >40%. The trial tested whether routine beta-blockers reduce death, reinfarction, or heart failure hospitalization.
🥸 1️⃣ The BETAMI–DANBLOCK trial, a large, pragmatic randomized trial from Denmark and Norway, asked whether long-term beta-blockers reduce death or cardiovascular events in post-MI patients with preserved or mildly reduced LVEF but no heart failure.
🥸1️⃣ ASPREE was a large randomized trial designed to evaluate whether daily low-dose aspirin prevents cardiovascular events in initially healthy older adults.
🥸1️⃣ Acute coronary syndromes remain a leading cause of global mortality, with one out of three deaths attributed to atherosclerosis and its acute or chronic complications.
🥸1️⃣ This Danish nationwide cohort study examined the 10-year risk of first-time infective endocarditis (IE) in patients after mitral valve (MV) replacement or repair, compared to those at moderate risk of IE, using high-quality registry data from 2000–2020.
🥸1️⃣ Alcohol use and cardiovascular disease (CVD) have a complicated and often debated relationship; this AHA statement reviews decades of research on coronary artery disease (CAD), stroke, heart failure (HF), arrhythmias, and cardiomyopathy.
🥸 1️⃣ SURMOUNT-5 directly compares tirzepatide and semaglutide for obesity in adults without diabetes. First head-to-head randomized trial of these two GLP-1–based agents. Published @NEJM, May 2025. 
🥸 1️⃣ Healthy ageing in cardiovascular disease matters because by 2050, adults 65+ will represent over 20% of the U.S. and nearly 30% of Europe's population, dramatically shifting healthcare needs.
🥸1️⃣ In cancer-associated VTE, extended anticoagulation is common—but the dose remains uncertain. The API-CAT trial tested reduced-dose vs. full-dose apixaban after 6 months of initial therapy.
🥸1️⃣ Lifetime cardiovascular risk increases with the number of classic risk factors you carry at age 50. The Global Cardiovascular Risk Consortium analyzed over 2 million people to estimate how much risk factors shorten life and healthspan.
🥸1️⃣ Elevated concentrations of lipoprotein(a) are a strong, independent risk factor for cardiovascular disease. Lepodisiran, a long-acting small interfering RNA, targets hepatic production of lipoprotein(a).
🥸1️⃣ In patients with suspected ACS, a 12-lead ECG should be acquired and interpreted within 10 minutes of first medical contact to identify patients with STEMI.
🥸 1️⃣ Hunger is an ancient survival mechanism that evolved to keep humans alive in times of food scarcity.
🥸 1️⃣ Abelacimab significantly reduced bleeding in atrial fibrillation patients compared to rivaroxaban, as reported in the AZALEA–TIMI 71 trial.